Your browser doesn't support javascript.
loading
Characteristics and outcomes of gallbladder cancer patients at the Tata Medical Center, Kolkata 2017-2019.
Dutta, Anindita; Mungle, Tushar; Chowdhury, Nandita; Banerjee, Pritha; Gehani, Anisha; Sen, Saugata; Mallath, Mohandas; Roy, Paromita; Krishnan, Shekhar; Ganguly, Sandip; Banerjee, Sudeep; Roy, Manas; Saha, Vaskar.
Afiliação
  • Dutta A; Cell Biology, Tata Translational Cancer Research Centre, Kolkata, India.
  • Mungle T; Division of Cancer Sciences, University of Manchester, Manchester, UK.
  • Chowdhury N; Clinical Research Unit, Tata Translational Cancer Research Centre, Kolkata, India.
  • Banerjee P; Cell Biology, Tata Translational Cancer Research Centre, Kolkata, India.
  • Gehani A; Clinical Research Unit, Tata Translational Cancer Research Centre, Kolkata, India.
  • Sen S; Department of Radiology, Tata Medical Center, Kolkata, India.
  • Mallath M; Department of Radiology, Tata Medical Center, Kolkata, India.
  • Roy P; Department of Digestive Diseases, Tata Medical Center, Kolkata, India.
  • Krishnan S; Department of Histopathology, Tata Medical Center, Kolkata, India.
  • Ganguly S; Division of Cancer Sciences, University of Manchester, Manchester, UK.
  • Banerjee S; Clinical Research Unit, Tata Translational Cancer Research Centre, Kolkata, India.
  • Roy M; Department of Paediatric Haematology and Oncology, Tata Medical Center, Kolkata, India.
  • Saha V; Department of Medical Oncology, Tata Medical Center, Kolkata, India.
Cancer Med ; 12(8): 9293-9302, 2023 04.
Article em En | MEDLINE | ID: mdl-36779618
BACKGROUND: The north and north-eastern regions of India have among the highest incidence of gallbladder cancer (GBC) in the world. We report the clinicopathological charateristics and outcome of GBC patients in India. METHODS: Electronic medical records of patients diagnosed with GBC at Tata Medical Center, Kolkata between 2017 and 2019 were analyzed. RESULTS: There were 698 cases of confirmed GBC with a median age of 58 (IQR: 50-65) years and female:male ratio of 1.96. At presentation, 91% (496/544) had stage III/IV disease and 30% (189/640) had incidental GBC. The 2-year overall survival (OS) was 100% (95% CI: 100-100); 61% (95% CI: 45-83); 30% (95% CI: 21-43); and 9% (95% CI: 6-13) for stages I-IV, respectively (p = <0.0001).   For all patients, the 2-year OS in patients who had a radical cholecystectomy followed by adjuvant therapy (N = 36) was 50% (95% CI: 39-64), compared to 29% (95% CI: 22-38) for those who had a simple cholecystectomy and/or chemotherapy (N = 265) and 9% (95% CI: 6-14) in patients who were palliated (N = 107) (p = <0.0001). CONCLUSION: The combined surgical/chemotherapy approach for patients with stage II GBC showed the best outcomes. Early detection of GBC remains problematic with the majority of patients presenting with stage III-IV and who have a median survival of 9.1 months. Our data suggests that the tumor is chemoresponsive and multi-center collaborative clinical trials to identify alternative therapies are urgently required.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma in Situ / Neoplasias da Vesícula Biliar Tipo de estudo: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma in Situ / Neoplasias da Vesícula Biliar Tipo de estudo: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2023 Tipo de documento: Article